UNSPSC 51312804: Mequitazine

This classification denotes an anti-allergic agent and bronchodilator with the molecular formula C20H22N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y463242LY2, chemically known as 10h-phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)- (9ci) but generally known as mequitazine, which bears US NIH Compound Identifier 4066. European Medicines Agency schedules Mequitazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08766MIG.

UNSPSC 51312804 Mequitazine is a Commodity code representing pharmaceutical products, but the recent state and local solicitations under this code do not target mequitazine specifically. Instead, Seminole County, Florida solicited naloxone and safe drug deactivation systems through IFB 60459723LAS (due July 26, 2023), the Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescription programs (April 3, 2026 response deadline), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products (March 26, 2026 due date). The code shows activity across state health agencies, county health departments, and cooperative purchasing vehicles. Work under the code spans emergency pharmaceutical supplies (naloxone), generic and OTC drug sourcing through established wholesaler networks, and exploratory procurement of direct-to-manufacturer pharmacy programs. Issuing bodies include state departments of health and human services, county health authorities, and multistate purchasing cooperatives serving participating state and local facilities.

Recent activity concentrates in Florida and Texas, with multistate reach through cooperative purchasing. Seminole County's procurement required 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, using competitive bidding with electronic submission and E-Verify compliance. The Texas HHS Commission's RFI sought vendor capabilities for direct contracting between state pharmacy benefit programs and manufacturers, exploring alternatives to traditional pharmacy benefit manager and group purchasing organization relationships. MMCAP's RFP, administered by Minnesota's Office of State Procurement and extending to Oregon, required manufacturers to supply pharmaceuticals through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) with strict compliance to cGMP, DSCSA certification, and pricing submitted in specified formats; the evaluation weighted price competitiveness at 75 percent, with a two-year initial contract term and optional extensions. The code shows limited recent activity specifically tied to mequitazine; the tagged opportunities span broader pharmaceutical procurement, suggesting potential tagging misalignment with the commodity-code scope.